Supplementary Sections S1-S13. S1 Pilot Study Summary S2 Exclusion criteria S3. Severity and disability outcome measures, with citations. S4. Methods for candidate biochemical markers, including equipment and citations. S5. Further methods for candidate biochemical markers, including equipment and citations S6. Summary of biomarker results. S7. Sample characteristics for recruitment outcomes, medications, data imputation. S8. Compound biomarkers of further theoretical interest S1 Pilot study summary A case series pilot study was conducted in [2007][2008][2009]. In this study, 10 out of 15 cases with schizophrenia (67%, P 0.002) and 7 out of 8 cases with auditory processing disorder (87%, P0.0002) had accumulated three or more abnormal biochemistry markers, when compared with 15 in-clinic selected control cases. These abnormal markers were for homocysteine, hydroxyhaempyrroline-2-one (HPL), folate, zinc, percent free copper and histamine. From these need for a minimum number of 60 cases and 60 matched controls, was estimated for 95% confidence interval power for a phase II casecontrol study.
learning disability. Persons with extra-pyramidal signs in ocular, arm or hand muscles were excluded prior to consent. Persons receiving vitamin therapy were also excluded due to the inclusion of vitamins as candidate markers. It was not possible to exclude smoking and have any chance of patient recruitment. Persons taking anti-histamine medication or vitamin supplementation similar to candidate markers, were also xcluded.
S3. Severity and disability outcome measures, with citations.
S4. Methods for candidate biochemical markers, including equipment and citations.
Functional Rating Scale Citation
The Brief Psychiatric Rating Scale (BPRS) Overall JE and Gorham DR (1962) -were diagnosed with schizophrenia and schizoaffective disorder -drawn from a sample pool of 22,000.
-4 eligible cases of psychosis were allocated a diagnosis of psychosis for investigation -Imposition of multiple exclusion criteria restricted eligible cases to 370 -only twenty five percent of these consented.
-This high refusal rate resulted in 89 consenting cases, -7 did not reach assessment due to declining mental state and -15 were excluded due to the confounding factor of SSRI, SNRI medication.
-number of cases in the final analysis was 67.
The control sample:
-was drawn from an available sample number of 2489.
-were matched for age and sex with patients.
-randomization and imposition of recruitment exclusion criteria -after a low consent rate of 25 per cent, a total of 72 control participants were recruited.
-5 of these were excluded due to failure to meet exclusion criteria on assessment.
-no control had a diagnosis of schizophrenia or any DSM-diagnosed mental illness, -all control participants were rated before biological assessment for reported and observed subclinical symptoms in a real-world setting, by a psychiatric trained assessor who was not blind to their study status. 
